

Market Outlook

After a strong start, the Nifty 50 surged to a new all-time high of 26,310, reflecting solid early momentum. However, the index was unable to hold onto these gains as profit-booking and Intraday volatility set in, pulling it down from the peak. It eventually settled at 26,215, still maintaining a healthy position despite the late decline. Immediate support now lies at 26,150–26,100, while resistance is placed at 26,300–26,400. Overall sentiment remains bullish with stock-specific action dominating.

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	26215	0.03
SENSEX	85720	0.12
BANKNIFTY	59737	0.35
INDIA VIX	11.78	-1.52

FII's STATISTICS


FII's F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	746.58	0.37%
Index Options	9264.20	3.47%
Stock Futures	-2613.97	0.60%
Stock Options	-710.43	29.42%

FII's & DII's Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	-1255.20	-13704	-123924
DII	3940.87	72934	515384

FII's Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
HDFCBANK	16830504	11.77	31
ETERNAL	13427109	5.39	56.02
ICICIBANK	10606393	6.24	56.94
POWERGRID	7165504	6.19	18.1
BAJFINANCE	6510318	-13.85	23.57
SBIN	6251102	-8.33	-14.59
RELIANCE	5655438	-3.18	-30.31
ITC	5374198	-6.53	-24.16
INFY	4672092	1.84	-0.3
NTPC	4196993	-1.33	-4.87


NIFTY

Nifty	26390.90
OI (In contracts)	197619
CHANGE IN OI (%)	-0.70
PRICE CHANGE (%)	0.00
IMPLICATION	NEUTRAL

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
LTIM	6067	2.20	15658	10.70
MOTHERSON	116.96	3.90	28380	10.30
ANGELONE	2721.1	0.00	11123	6.30
LAURUSLABS	1011.4	2.10	20345	5.00
ASHOKLEY	156.8	4.50	25669	10.30


BANKNIFTY

Banknifty	60031.80
OI (In contracts)	48207
CHANGE IN OI (%)	7.40
PRICE CHANGE (%)	0.40
IMPLICATION	LONG BUILDUP

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
KAYNES	5608.5	-3.90	21839	22.00
ADANIET	2265.6	-2.60	54982	10.00
TIINDIA	2854.5	-1.60	11263	8.20
EICHERMOT	7046.5	-2.50	18778	7.40
OFSS	8210	-0.30	18095	6.10

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
HEROMOTOCO	3194550	2882250	1.11
PETRONET	19326800	17477900	1.11
AUBANK	7195000	6602000	1.09
CANBK	130754250	121263750	1.08
SBILIFE	3166125	3091125	1.02
VOLTAS	3981000	3907500	1.02
FEDERALBNK	46360000	45845000	1.01
ABCAPITAL	20773100	21064500	0.99
PERSISTENT	801300	816100	0.98
MCX	2301500	2374750	0.97

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
KAYNES	1304800	3490800	0.37
PATANJALI	3450600	9377100	0.37
PPLPHARMA	6871375	17901250	0.38
TATASTEEL	118932000	313874000	0.38
SUZLON	91198700	222043175	0.41
TMPV	35598400	87476800	0.41
YESBANK	252905200	612203500	0.41
NCC	11504700	27418500	0.42
DELHIVERY	10412350	24072075	0.43
NESTLEIND	2830500	6592500	0.43

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2313	2360	2284	2236	2207
ADANIPORTS	1524	1530	1517	1511	1504
APOLLOHOSP	7456	7536	7408	7329	7281
ASIANPAINT	2919	2946	2902	2875	2857
AXISBANK	1307	1320	1297	1283	1273
BAJAJ-AUTO	9250	9413	9148	8984	8882
BAJAJFINSV	2138	2156	2115	2096	2073
BAJFINANCE	1056	1070	1037	1023	1004
BEL	419	422	417	414	412
BHARTIARTL	2145	2160	2131	2117	2103
CIPLA	1541	1547	1536	1530	1524
COALINDIA	381	382	379	378	377
DRREDDY	1262	1269	1256	1249	1243
EICHERMOT	7179	7312	7098	6965	6884
ETERNAL	310	314	306	301	298
GRASIM	2771	2785	2751	2738	2718
HCLTECH	1645	1655	1635	1625	1615
HDFCBANK	1023	1033	1013	1004	993
HDFCLIFE	788	794	784	779	775
HINDALCO	819	826	812	805	799
HINDUNILVR	2468	2482	2450	2437	2419
ICICIBANK	1405	1411	1394	1387	1376
INDIGO	5971	5999	5941	5914	5884
INFY	1580	1591	1568	1557	1545
ITC	408	409	406	405	404

SYMBOL	R1	R2	PP	S1	S2
JIOFIN	311	314	309	306	304
JSWSTEEL	1178	1188	1162	1153	1136
KOTAKBANK	2145	2165	2125	2106	2086
LT	4150	4193	4119	4077	4046
M&M	3736	3765	3713	3683	3660
MARUTI	16207	16397	16097	15907	15797
MAXHEALTH	1173	1177	1168	1163	1158
NESTLEIND	1286	1297	1278	1267	1258
NTPC	331	333	329	328	326
ONGC	249	253	247	243	241
POWERGRID	277	279	276	275	274
RELIANCE	1584	1593	1575	1565	1556
SBILIFE	2036	2055	2026	2007	1997
SBIN	992	1004	984	971	963
SHRIRAMFIN	876	881	869	864	857
SUNPHARMA	1826	1834	1815	1807	1796
TATACONSUM	1197	1210	1187	1174	1164
TATASTEEL	171	173	170	168	166
TCS	3191	3223	3167	3135	3112
TECHM	1537	1555	1524	1506	1494
TITAN	3957	3983	3930	3904	3877
TMPV	364	367	361	358	355
TRENT	4335	4374	4304	4265	4234
ULTRACEMCO	11812	11923	11749	11638	11575
WIPRO	253	255	251	249	247

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com
<i>Vivek Chandra</i>	vivek.chandra@religare.com
<i>Himanshu Gupta</i>	himanshu.gupta1@religare.com
<i>Vishvajeet Singh</i>	vishvajeet.singh1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results